UBS Downgrades US Stock Market
Reflecting shifting sentiment, UBS has downgraded its outlook for U.S. stocks. The bank warns that key drivers of past performance, like corporate buybacks, are weakening. UBS flagged "asymmetric structural downside risks" to the dollar and cited persistent inflation and geopolitical risk as major concerns.
The downgrade, authored by UBS's Head of Global Equity Strategy Andrew Garthwaite, shifts the bank's recommendation for U.S. stocks from "overweight" to a more cautious "neutral" benchmark position within a global portfolio. Concurrently, the firm is maintaining a high-conviction "overweight" stance on emerging market equities, anticipating a rotation of capital to regions with more attractive growth prospects. A key driver of the downgrade is valuation. U.S. stocks are trading at a price-to-earnings ratio that is 35% higher than their international peers, a significant jump from the average premium of just 4% seen since 2010. UBS forecasts the euro will strengthen to $1.22 against the dollar and notes the U.S. dollar index has already fallen nearly 9% over the past year. Historically, a 10% drop in the dollar's trade-weighted index has led to U.S. stocks underperforming global markets by about four percentage points. The advantage from corporate buybacks has evaporated, with U.S. buyback yields now merely on par with the rest of the world. The combined shareholder return from both dividends and buybacks in the United States is now approximately half of that in Europe. This sentiment shift follows tangible market trends. So far this year, the S&P 500 has remained largely flat, while Japan's Nikkei 225 has surged 17%, and Europe's Stoxx 600 has climbed 7%. The downgrade coincides with hotter-than-expected inflation data. The January Producer Price Index (PPI) rose 0.5%, surpassing the 0.3% consensus forecast and fueling concerns that price pressures are becoming a structural issue. Policy uncertainty in Washington is adding another layer of risk. The UBS report noted potential headwinds from shifting tariff policies, proposals to cap credit card interest rates, and renewed scrutiny of drug pricing.
